Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

5.3K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Characterization of Melanoma of Unknown Primary in the Era of Immunotherapy and Targeted Therapy in Spain: Results from the Prospective Real World Study GEM 1801.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2026
Same author

Real-world effectiveness of chemotherapy regimens after immunotherapy in patients with advanced melanoma in Spain: Results from the GEM1801 study.

Cancer·2026
Same author

First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors.

Journal for immunotherapy of cancer·2026
Same author

Subcutaneous immunotherapy as a catalyst for decentralized, oncologist-led cancer care: a mixed-methods analysis.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2026
Same author

Quality and safety of research biopsies in oncology clinical trials.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Discontinuation of combo immunotherapy and outcome of patients with melanoma brain metastases.

Journal for immunotherapy of cancer·2026

Related Experiment Video

Updated: Feb 23, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

16.7K

NRAS-mutant melanoma: current challenges and future prospect.

Eva Muñoz-Couselo1,2, Ester Zamora Adelantado1,2, Carolina Ortiz1,2

  • 1Medical Oncology Department, Vall d'Hebron Hospital, Barcelona, Spain.

Oncotargets and Therapy
|September 2, 2017
PubMed
Summary

NRAS-mutant melanoma is aggressive, but patients may respond better to immunotherapy. Combining MEK and CDK4/6 inhibitors shows promise for future NRAS-mutant melanoma treatment strategies.

Keywords:
MEK inhibitorNRAS mutationbinimetinibimmunotherapymetastatic melanomatrametinib

More Related Videos

A Melanoma Patient-Derived Xenograft Model
07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

13.3K
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.9K

Related Experiment Videos

Last Updated: Feb 23, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

16.7K
A Melanoma Patient-Derived Xenograft Model
07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

13.3K
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.9K

Area of Science:

  • Oncology
  • Cancer Genetics
  • Dermatology

Background:

  • Melanoma is a common skin cancer, with NRAS mutations found in 15-20% of cases.
  • NRAS-mutant melanoma is more aggressive and linked to poorer patient outcomes.
  • Current treatments for NRAS-mutant melanoma offer limited survival benefits.

Purpose of the Study:

  • To review the current understanding and treatment landscape of NRAS-mutant melanoma.
  • To explore potential therapeutic strategies, including combination therapies and immunotherapy.
  • To highlight the need for improved treatment approaches for this aggressive melanoma subtype.

Main Methods:

  • Literature review of studies on NRAS-mutant melanoma.
  • Analysis of preclinical data and clinical trial outcomes.
  • Evaluation of response to immunotherapy and targeted therapies.

Main Results:

  • NRAS-mutant melanoma patients show better responses to immunotherapy compared to other subtypes.
  • Combination therapies, such as MEK and CDK4/6 inhibition, show potential.
  • Current targeted therapies provide modest progression-free survival but no overall survival benefit.

Conclusions:

  • NRAS-mutant melanoma requires novel therapeutic strategies.
  • Immunotherapy, particularly immune checkpoint inhibitors, may be highly effective.
  • Combination of MEK and CDK4/6 inhibition is a promising future treatment option.